Bernstein Liebhard LLP Investigating Diabetes Drug Lawsuits Involving Byetta, Januvia, Victoza and Similar Medications

June 16, 2013

The Firm is investigating diabetes drug lawsuits on behalf of patients who took Byetta, Januvia, Victoza or similar medications and were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer.

New York, New York (PRWEB) June 16, 2013

The nationwide law firm of Bernstein Liebhard LLP is investigating diabetes drug lawsuits on behalf of patients treated with Byetta, Januvia, Victoza and other medications known as incretin mimetics, and who have been diagnosed with pancreatitis, pancreatic cancer or thyroid cancer. Type II diabetics who were treated with an incretin mimetic and who were diagnosed with one of these diseases may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. Medications included in the Firm´s diabetes drug lawsuit investigation include:

  •     Byetta
  •     Bydureon
  •     Victoza
  •     Januvia
  •     Janumet
  •     Janumet XR
  •     Juvisync
  •     Onglyza
  •     Kombiglyze XR
  •     Nesina
  •     Kazano
  •     Oseni
  •     Tradjenta

“Recent regulatory action and studies have increased concerns that Byetta, Januvia, Victoza and similar drugs could be associated with an increased risk of pancreatitis, pancreatic cancer and thyroid cancer. Our Firm is anxious to hear from anyone who used these medications and was diagnosed with one of these disorders,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free diabetes drug lawsuit consultations to potential victims of these drugs.

Incretin Mimetics

According to the U.S. Food & Drug Administration (FDA), incretin mimetics like Januvia, Byetta and Victoza are used in combination with diet and exercise to reduce blood sugar levels in people with type II diabetes. They work by mimicking incretin hormones, which the body would normally produce to stimulate the release of insulin in response to a meal. On March 14, 2013, the FDA announced it was investigating findings from an unpublished study that indicated the use of these drugs could be associated with cellular changes in the pancreas called pancreatic duct metaplasia, a precursor to cancer.*

Prior to the FDA´s communication, a study published in February 2011 in Gastroenterology reported that use of Januvia and Byetta may increase the risk for pancreatitis as much as six-fold.** In February 2013, a paper published in JAMA Internal Medicine reported that Byetta and Januvia appeared to double the risk for pancreatic cancer.***

Over the past several years, the FDA has also issued cautions for individual incretin mimetics. For example, in 2008, the agency revealed that Byetta had been associated with a high number of adverse event reports involving pancreatits.**** It issued a similar communication for Januvia in 2009.***** In 2011, the FDA warned of a potential risk of thyroid cancer associated with Victoza.******

Court documents indicate that a motion has been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) that seeks to have all federally-filed product liability lawsuits involving incretin mimetics transferred to a single federal court for pretrial proceedings. The Panel is expected to hear Oral Arguments on the issue during its July 25th Hearing Session. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Patients treated with Byetta, Januvia, Victoza or other incretin mimetics are urged to contact Bernstein Liebhard LLP for a free legal consultation if they were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer with one of these drugs. To learn more about the Firm´s diabetes drug lawsuit investigation, please call 800-511-5092.

  • fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013

** gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

***archinte.jamanetwork.com/article.aspx?articleid=1656537, JAMA Internal Medicine, February 25, 2013

****fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008

*****fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm; September 25, 2009

******fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm, FDA, June 13, 2011

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016


ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebdiabetes-drug-lawsuit/pancreatic-cancer/prweb10837515.htm

Source: prweb

comments powered by Disqus